New at CADTH - June 2021

News and Events

Canada's Drug Agency Symposium 2021 — Call for Abstracts

Canada's Drug Agency is now accepting abstracts for the 2021 Canada's Drug Agency Symposium. This year’s theme is Uncertain Times, Imperfect Evidence, and the Imperative to Act. Topics relevant to this theme include, but are not limited to, real-world evidence, virtual health care, and drugs for rare diseases. The Call for Abstracts submission deadline is Tuesday, June 22, 2021.

Canada's Drug Agency Symposium 2021 — Call for Abstract Reviewers

OCanada's Drug Agency is looking for volunteers to review abstracts for the 2021 Canada's Drug Agency Symposium. This is a great way to participate in developing a stellar program that will feature relevant and engaging topics in a wide variety of formats: workshops, oral presentations, poster presentations, panel discussions, debates, and breakfast sessions. If you’re interested in joining the Abstract Review Committee, deadline to submit your application by Tuesday, June 22, 2021.

New Report with Choosing Wisely Canada Highlights Recommendations to Reduce Low-Value Care Post-Pandemic

A new report from Choosing Wisely Canada (CWC) and Canada's Drug Agency looks ahead to post-pandemic health care in Canada. The report highlights consensus on evidence-based recommendations to reduce low-value care when health systems are ready to gradually resume the services and procedures that were put on hold due to COVID-19.

“Canada's Drug Agency in Conversation with…” - a new Canada's Drug Agency speaker series

Canada's Drug Agency is excited to announce a new speaker series called “Canada's Drug Agency in Conversation with…”. This series features our President and CEO, Suzanne McGurn, talking to leading Canadian and global decision-makers in health care, value assessment, and health technology management. Stay tuned for the official launch in the fall of 2021.

Want to learn more about our work on COVID-19? Visit our Canada's Drug Agency COVID Evidence Portal.

Canada's Drug Agency REIMBURSEMENT REVIEWS

Canada's Drug Agency recently issued the following reimbursement recommendations:

• Ranolazine (Corzyna) - Stable angina pectoris, adults
• Brigatinib (Alunbrig) for Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
• Polatuzumab Vedotin (Polivy) for diffuse large B-cell lymphoma
• Niraparib (Zejula) for first line Ovarian Cancer
• Olaparib (Lynparza) for metastatic castration-resistant prostate cancer
• Sonidegib (Odomzo) for Basal Cell Carcinoma
• unresectable hepatocellular carcinoma — Provisional Funding Algorithm
• Chronic lymphocytic leukemia — Provisional Funding Algorithm

Canada's Drug Agency HEALTH TECHNOLOGY REVIEWS

Canada's Drug Agency recently published the following health technology reviews:

• Tuberculosis Screening for People with Chronic Conditions — Rapid Review
• Visual Examination Frequency for People Taking Ethambutol for Tuberculosis — Rapid Review
• Conventional Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis — Rapid Review
• Treat and Release for Patients Requiring Emergency Medical Services — Rapid Review
• Interferon Gamma Release Assay for Identifying Latent Tuberculosis Infection in People With Bacillus Calmette-Guérin Vaccination — Rapid Review
• Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer — Rapid Review with Expert Input
• Overview of Formulary Management Practices of Publicly Funded Provincial and Territorial Drug Plans — Environmental Scan
• Electronic Aids to Daily Living — Environmental Scan
• Framework for Drugs for Rare Diseases — Environmental Scan
• Single-Entry Models in Surgical Services — Policy Insight
• Evidence Update on Direct Oral Anticoagulants for Atrial Fibrillation
• Analysis of FPT Formulary Harmonization: Specialty Care Medications

Canada's Drug Agency REFERENCE LISTS

Canada's Drug Agency recently completed the following reference lists:

• Midazolam for Patients in Palliative Care — Reference List
• Extracorporeal Membrane Oxygenation for Adults and Children With Severe Hypoxic and Hypercarbic Respiratory Failure — Reference List
• Low-Dose 5-Year Intrauterine Devices for Treatment of Endometriosis — Reference List
• Pharmacological and Non-Pharmacological Vaping Cessation Interventions for Youth —Reference List
• Transitional Pain Services for Patients Undergoing Surgery — Summary of Abstracts
• Nasal Cannula Combined With Non-Rebreather Masks for Delivery of Oxygen for Delivery of Oxygen — Summary of Abstracts
• Management of Patients Co-Prescribed Benzodiazepines and Opioids — Summary of Abstracts
• Bupropion for Major Depressive Disorder, Dysthymia, or Treatment-Resistant Depression —Summary of Abstracts
• Strategies for the Reduction or Discontinuation of Opioids: A 2021 Update — Summary of Abstracts
• Confocal Microscopy for Diagnosis and Management of Neuropathic Corneal Pain — Summary of Abstracts
• Ozonated Sinks for Infection Prevention — Summary of Abstracts
• Switching From Reference to Biosimilar Filgrastim in Pediatric Patients — Summary of Abstracts

Canada's Drug Agency HORIZON SCANNING

Canada's Drug Agency recently published the following horizon scans:

• At-Home Testing for Severe Acute Respiratory Syndrome Coronavirus 2 — Horizon Scan

OTHER Canada's Drug Agency TOOLS

Canada's Drug Agency recently developed the following tools:

• Tools:
  • Codeine for Pain: A Synopsis of the Evidence
  • Biosimilar Drugs: Your Questions Answered
• Hospital News articles: 
  • Human vs artificial intelligence: How well does AI detect lung cancer?
  • Considerations for integrating pharmacogenomics into health care
  • Considering the place of codeine in the treatment of osteoarthritis pain

TELL US WHAT YOU THINK

We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please get in touch with your Canada's Drug Agency Liaison Officer.

Canada's Drug Agency E-Alerts: Subscribe to receive the latest Canada's Drug Agency news, reports, feedback opportunities, and events.